J&J (JNJ) Talks to Sell Hips-and-Knees Business for $20 Billion
Published on · Source: wsj.com
AI Summary
Summarized by AI from the source belowJohnson & Johnson (JNJ) is in discussions to sell its hips-and-knees business to Apollo Global Management for approximately $20 billion. This potential divestiture is part of J&J's strategy to focus on core businesses and improve operational efficiency. If finalized, this deal could impact J&J's financial position and possibly affect its stock price. The move signals a significant shift in the company’s strategy, which is vital information for investors considering the financial health and direction of J&J.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Johnson & Johnson (JNJ)
Johnson & Johnson is a healthcare giant spanning pharmaceuticals and medical devices, known for its deep drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier JNJ news
- Apollo Global (APO) in Talks for J&J Orthopedics Unit Acquisition
- Johnson & Johnson (JNJ) Receives CE Mark for New Contact Lens
- J&J (JNJ) Continues Climb as Key Drivers Support Record Highs
- Johnson & Johnson (JNJ) Named Top Dividend Stock to Buy Now
- Johnson & Johnson Signals Strong Dividend Stock Potential
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
